Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of Viekirax + Exviera + ribavirin in decompensated HCV cirrhosis
2015-003152-43Phase 3Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paritaprevir, dasabuvir and ribavirin in hepatitis C virus infection and Cirrhosis, sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Improvement of liver function. Started Nov 2015; status: terminated.
02
Drugs
paritaprevirdasabuvirribavirin
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on 2015-003152-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003152-43.